1. (Once Amended.) A purified polypeptide comprising an amino acid sequence selected from the group consisting of:

a) the amino acid sequence of SEQ ID NO:2,

b) a naturally-occurring amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:2,

B1 c) a biologically active fragment of the polypeptide having the amino acid sequence of SEQ ID NO:2, and

d) an immunogenic fragment of the polypeptide having the amino acid sequence of SEQ ID NO:2.

2. (Once Amended.) An isolated polypeptide of claim 1, having the amino acid sequence of SEQ ID NO:2.

---

24. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and

N.E. b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

28. An isolated antibody which specifically binds to a polypeptide of claim 1.

---

29. (Once Amended.) A diagnostic test for a condition or disease associated with the expression of GIPL in a biological sample comprising the steps of:

B2 a) combining the biological sample with an antibody of claim 28, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and

b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

---

30. The antibody of claim 28, wherein the antibody is:

N.E. a) a chimeric antibody,

b) a single chain antibody,

c) a Fab fragment,

d) a $F(ab')_2$ fragment, or

e) a humanized antibody.

31. A composition comprising an antibody of claim 28 and an acceptable excipient.

32. (Once Amended.) A method of diagnosing a condition or disease associated with the expression of GIPL in a subject, comprising administering to said subject an effective amount of the composition of claim 31.

33. A composition of claim 31, wherein the antibody is labeled.

34. (Once Amended.) A method of diagnosing a condition or disease associated with the expression of GIPL in a subject, comprising administering to said subject an effective amount of the composition of claim 33.

35. (Once Amended.) A method of preparing a polyclonal antibody with the specificity of the antibody of claim 28 comprising:

a) immunizing an animal with a polypeptide having the amino acid sequence of SEQ ID NO:2, or an immunogenic fragment thereof, under conditions to elicit an antibody response;

b) isolating antibodies from said animal; and

c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having the amino acid sequence of SEQ ID NO:2.

36. An antibody produced by a method of claim 35.

37. A composition comprising the antibody of claim 36 and a suitable carrier.

38. (Once Amended.) A method of making a monoclonal antibody with the specificity of the antibody of claim 28 comprising:

a) immunizing an animal with a polypeptide having the amino acid sequence of SEQ ID NO:2, or an immunogenic fragment thereof, under conditions to elicit an antibody response;

B5

b) isolating antibody producing cells from the animal;

c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;

d) culturing the hybridoma cells; and

e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having the amino acid sequence of SEQ ID NO:2.

39. A monoclonal antibody produced by a method of claim 38.

40. A composition comprising the antibody of claim 39 and a suitable carrier.

N.E.

41. The antibody of claim 28, wherein the antibody is produced by screening a Fab expression library.

42. The antibody of claim 28, wherein the antibody is produced by screening a recombinant immunoglobulin library.

43. (Once Amended.) A method for detecting a polypeptide having the amino acid sequence of SEQ ID NO:2 in a sample, comprising the steps of:

a) incubating the antibody of claim 28 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

B6

b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having the amino acid sequence of SEQ ID NO:2 in the sample.

44. (Once Amended.) A method of purifying a polypeptide having the amino acid sequence of SEQ ID NO:2 from a sample, the method comprising:

B cont'd

a) incubating the antibody of claim 28 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

b) separating the antibody from the sample and obtaining the purified polypeptide having the amino acid sequence of SEQ ID NO:2.